ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three major investor conferences in February 2025. The company will engage in fireside chats at the following events:
- Jones Research Precision Medicine Day on February 3 at 12:30 p.m. ET
- Guggenheim Securities SMID Cap Biotech Conference on February 5 at 1:30 p.m. ET
- Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 12:00 p.m. ET
Live webcasts of these discussions will be accessible through the investor section of ORIC's website at www.oricpharma.com, with replays available for 90 days after each event.
Positive
- None.
Negative
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
- Jones Research Precision Medicine Day – Participating in a fireside chat on Monday, February 3, 2025, at 12:30 p.m. ET
- Guggenheim Securities SMID Cap Biotech Conference – Participating in a fireside chat on Wednesday, February 5, 2025, at 1:30 p.m. ET
- Oppenheimer 35th Annual Healthcare Life Sciences Conference – Participating in a fireside chat on Tuesday, February 11, 2025, at 12:00 p.m. ET
Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What investor conferences will ORIC Pharmaceuticals attend in February 2025?
How can investors access ORIC Pharmaceuticals' conference presentations in February 2025?
What time is ORIC's presentation at the Oppenheimer Healthcare Conference on February 11, 2025?
How long will the replays of ORIC's February 2025 conference presentations be available?
